Published in Food and Drug Law Weekly, June 25th, 2004
Terbutaline is indicated for the prevention and reversal of bronchospasm in patients over the age of 12 with bronchial asthma and reversible bronchospasm associated with bronchitis and emphysema, and is the generic equivalent of aaiPharma, Inc.'s Brethine Injection. APP expects to commence marketing terbutaline shortly.
"We received this ANDA approval only 7 months after it was submitted, which underscores the ability of our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.